Todd Franklin Watanabe Arcutis Biotherapeutics, Inc. (ARQT) insider trading activity

Todd Franklin Watanabe is Director of Arcutis Biotherapeutics, Inc.. Currently has a direct ownership of 846,440 shares of ARQT, which is worth approximately $17.7 Million. The most recent transaction as insider was on Oct 02, 2025, when has been sold 20,739 shares (Common Stock) at a price of $20.04 per share, resulting in proceeds of $415,609. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 846K

7.3% 3M change

0.02% 12M change

Total Value Held $17.7 Million

Todd Franklin Watanabe Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 02 2025	SELL Open market or private sale	$415,609 $20.04 p/Share	20,739 Reduced 2.39%	846,440 Common Stock
Oct 01 2025	SELL Open market or private sale	$472,361 $19.47 p/Share	24,261 Reduced 2.72%	867,179 Common Stock
Sep 09 2025	SELL Open market or private sale	$8,830 $17.52 p/Share	504 Reduced 0.06%	891,440 Common Stock
Sep 08 2025	SELL Open market or private sale	$168,822 $17.54 p/Share	9,625 Reduced 1.07%	891,944 Common Stock
Aug 04 2025	SELL Open market or private sale	$165,468 $14.33 p/Share	11,547 Reduced 1.26%	901,569 Common Stock
Jun 10 2025	SELL Bona fide gift	-	1,994 Reduced 0.22%	913,116 Common Stock
May 02 2025	SELL Open market or private sale	$173,895 $15.19 p/Share	11,448 Reduced 1.24%	913,795 Common Stock
Mar 25 2025	SELL Open market or private sale	$38,122 $17.56 p/Share	2,171 Reduced 0.23%	925,243 Common Stock
Mar 24 2025	SELL Open market or private sale	$26,280 $17.52 p/Share	1,500 Reduced 0.16%	927,414 Common Stock
Mar 17 2025	SELL Open market or private sale	$21,132 $17.61 p/Share	1,200 Reduced 0.13%	928,914 Common Stock
Mar 04 2025	SELL Open market or private sale	$54,912 $13.28 p/Share	4,135 Reduced 0.44%	930,114 Common Stock
Mar 03 2025	SELL Open market or private sale	$272,066 $13.03 p/Share	20,880 Reduced 2.19%	934,249 Common Stock
Feb 28 2025	BUY Grant, award, or other acquisition	-	151,000 Added 13.65%	955,129 Common Stock
Feb 03 2025	SELL Open market or private sale	$245,122 $12.7 p/Share	19,301 Reduced 2.34%	804,129 Common Stock
Dec 20 2024	SELL Open market or private sale	$227,550 $15.17 p/Share	15,000 Reduced 1.79%	823,430 Common Stock
Nov 30 2024	BUY Open market or private purchase	$14,490 $7.11 p/Share	2,038 Added 0.24%	838,430 Common Stock
Nov 04 2024	SELL Open market or private sale	$120,400 $8.68 p/Share	13,871 Reduced 1.64%	832,392 Common Stock
Aug 02 2024	SELL Open market or private sale	$130,672 $9.02 p/Share	14,487 Reduced 1.68%	846,263 Common Stock
May 31 2024	BUY Open market or private purchase	$6,760 $1.69 p/Share	4,000 Added 0.48%	836,392 Common Stock
May 02 2024	SELL Open market or private sale	$120,463 $8.74 p/Share	13,783 Reduced 1.58%	860,750 Common Stock
Mar 04 2024	SELL Open market or private sale	$165,721 $11.12 p/Share	14,903 Reduced 1.68%	874,533 Common Stock
Feb 28 2024	SELL Open market or private sale	$26,129 $10.6 p/Share	2,465 Reduced 0.28%	889,436 Common Stock
Feb 13 2024	BUY Grant, award, or other acquisition	-	264,882 Added 22.9%	891,901 Common Stock
Jan 12 2024	BUY Grant, award, or other acquisition	-	125,000 Added 16.62%	627,019 Common Stock
Dec 20 2023	SELL Bona fide gift	-	13,126 Reduced 2.55%	502,019 Common Stock

TFW

Todd Franklin Watanabe

Director

Westlake Village, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARQT shares.

Notify only if

Value

Insider Trading

Get notified when an Arcutis Biotherapeutics, Inc. insider buys or sells ARQT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Arcutis Biotherapeutics, Inc.

Track Activities on ARQT

Account